Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
becotarug (JMT101)
i
Other names:
JMT101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
CSPC Pharma
Drug class:
EGFR inhibitor
Related drugs:
‹
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
necitumumab (3)
befotertinib (3)
zorifertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
MCLA-129 (3)
DZD9008 (3)
SZMD4 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
necitumumab (3)
befotertinib (3)
zorifertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
MCLA-129 (3)
DZD9008 (3)
SZMD4 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
›
Associations
(1)
News
Trials
Filter by
Latest
9d
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations (clinicaltrials.gov)
P3, N=516, Recruiting, Shanghai JMT-Bio Inc.
9 days ago
New P3 trial • Combination therapy • Metastases
|
Tagrisso (osimertinib) • becotarug (JMT101)
8ms
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations (clinicaltrials.gov)
P2, N=161, Active, not recruiting, Shanghai JMT-Bio Inc.
8 months ago
New P2 trial
|
Tagrisso (osimertinib) • becotarug (JMT101)
8ms
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations (clinicaltrials.gov)
P3, N=398, Not yet recruiting, Shanghai JMT-Bio Inc.
8 months ago
New P3 trial • Combination therapy • EGFR exon 20 • Metastases
|
cisplatin • Tagrisso (osimertinib) • pemetrexed • becotarug (JMT101)
9ms
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2/3, N=534, Not yet recruiting, Shanghai JMT-Bio Inc.
9 months ago
New P2/3 trial
|
docetaxel • becotarug (JMT101)
1year
A Study of JMT101 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
P2, N=102, Not yet recruiting, Shanghai JMT-Bio Inc.
1 year ago
New P2 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
MSI-H/dMMR • BRAF wild-type
|
Stivarga (regorafenib) • irinotecan • becotarug (JMT101)
over1year
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. (PubMed, Nat Commun)
Intracranial disease control rate is 87.5%. Confirmed intracranial objective response rate is 25%.
over 1 year ago
P1 data • Journal • EGFR exon 20
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • becotarug (JMT101)
3years
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=155, Not yet recruiting, Shanghai JMT-Bio Inc.
3 years ago
Clinical • New P2 trial • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • becotarug (JMT101)
over3years
[VIRTUAL] JMT101 Combined With Afatinib or Osimertinib in Patients (pts) With NSCLC With EGFR Exon 20 Insertion Mutations (IASLC-WCLC 2021)
The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.
over 3 years ago
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • Gilotrif (afatinib) • becotarug (JMT101)
almost4years
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=259, Recruiting, Shanghai JMT-Bio Inc.
almost 4 years ago
Clinical • New P1 trial
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • becotarug (JMT101)
over4years
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=48, Recruiting, Shanghai JMT-Bio Inc. | Not yet recruiting --> Recruiting
over 4 years ago
Clinical • Enrollment open • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • Gilotrif (afatinib) • becotarug (JMT101)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login